# Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Study · id `cardio:ct-nct07632898` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07632898](<https://clinicaltrials.gov/study/NCT07632898>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07632898

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 484 participants.

## Technical summary

Registry record NCT07632898. Allocation not applicable; no masking; primary purpose treatment. Start 2026-10-23 (anticipated); primary completion 2030-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 484 participants (planned count; ClinicalTrials.gov record NCT07632898, source copy `cardio:ctgov-nct07632898-2026-06-08`, retrieved 2026-10-31)
- Planned start: 2026-10-23 (anticipated) (ClinicalTrials.gov record NCT07632898, source copy `cardio:ctgov-nct07632898-2026-06-08`, retrieved 2026-10-31)
- Primary completion: 2030-06-30 (anticipated) (ClinicalTrials.gov record NCT07632898, source copy `cardio:ctgov-nct07632898-2026-06-08`, retrieved 2026-10-31)
- Completion: 2030-12-30 (anticipated) (ClinicalTrials.gov record NCT07632898, source copy `cardio:ctgov-nct07632898-2026-06-08`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07632898-2026-06-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
- Condition: Pulmonary Arterial Hypertension (PAH)
- Intervention (Drug): IKT-001
- Lead sponsor: Inhibikase Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: e72f6e10eacc0601a89f17503c400bd08eb99b9c6eda08aacc9b482bee62f520
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
